FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155327861> ?p ?o ?g. }

• W2155327861 endingPage "1159" @default.
• W2155327861 startingPage "1152" @default.
• W2155327861 abstract "Background. To study the feasibility of a response-guided therapy for chronic hepatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus (HIV) in a tertiary care hospital. Methods. Treatment duration was individualized on the basis of week 4 and week 12 virologic response. Sixty patients were enrolled and received pegylated interferon alfa-2b (1.5 μg/kg per week) plus weight-based ribavirin (800–1400 mg/day). Patients who achieved a rapid virologic response, defined as viral load <50 IU/mL at treatment week 4, completed 24 weeks of therapy. Patients who did not achieve a rapid virologic response were reassessed at treatment week 12. Patients with a complete early virologic response, defined as an HCV RNA level <600 IU/mL, were treated for 48 weeks. Patients with a partial response, defined as a decrease in the viral load ⩾2 log>10 and an HCV RNA level ⩾600 IU/mL, who attained an undetectable viral load at week 24 were treated for 60 weeks. The primary efficacy end point was sustained virologic response, defined as HCV RNA <50 IU/mL, 24 weeks after the end of treatment. Results. Overall, 33 (55%) of 60 patients achieved a sustained virologic response: 11 (44%) of 25 patients with HCV genotype 1, 3 (27%) of 11 patients with genotype 4, and 19 (79%) of 24 patients with genotype 3. One-third of patients showed a rapid virologic response. Of patients with genotype 1, there was a rapid virologic response in 4 (16%) of 25; with genotype 4, in 1 (9%) of 11; and with genotype 3, in 14 (58%) of 24. Of the 19 patients with a rapid virologic response, 17 (89.5%) eradicated the virus after 24 weeks of therapy. The rate of sustained virologic response was significantly higher among patients with genotype 3 and low pretreatment HCV RNA levels. A high relapse rate (46%) after 48 weeks of therapy occurred among patients infected with genotypes 1 or 4 who first achieved undetectable viral load at treatment week 12. Conclusion. A response-guide therapy is feasible and may be useful to optimize the individual outcome of HCV treatment in patients coinfected with HIV." @default.
• W2155327861 created "2016-06-24" @default.
• W2155327861 creator A5001003748 @default.
• W2155327861 creator A5007133273 @default.
• W2155327861 creator A5014359296 @default.
• W2155327861 creator A5029225176 @default.
• W2155327861 creator A5029683655 @default.
• W2155327861 creator A5043509211 @default.
• W2155327861 creator A5047015665 @default.
• W2155327861 creator A5058669821 @default.
• W2155327861 creator A5059398898 @default.
• W2155327861 creator A5062643699 @default.
• W2155327861 creator A5069448022 @default.
• W2155327861 creator A5082705335 @default.
• W2155327861 creator A5087175375 @default.
• W2155327861 creator A5037926233 @default.
• W2155327861 date "2009-04-15" @default.
• W2155327861 modified "2023-10-17" @default.
• W2155327861 title "Response‐Guided Therapy for Chronic Hepatitis C Virus Infection in Patients Coinfected with HIV: A Pilot Trial" @default.
• W2155327861 cites W1967080996 @default.
• W2155327861 cites W1970053808 @default.
• W2155327861 cites W1970734373 @default.
• W2155327861 cites W1978741605 @default.
• W2155327861 cites W1980390916 @default.
• W2155327861 cites W1985241178 @default.
• W2155327861 cites W1986283951 @default.
• W2155327861 cites W1992239172 @default.
• W2155327861 cites W1993484328 @default.
• W2155327861 cites W1996434966 @default.
• W2155327861 cites W2008741596 @default.
• W2155327861 cites W2023419369 @default.
• W2155327861 cites W2024043429 @default.
• W2155327861 cites W2027912196 @default.
• W2155327861 cites W2034654277 @default.
• W2155327861 cites W2035427845 @default.
• W2155327861 cites W2043068610 @default.
• W2155327861 cites W2061501244 @default.
• W2155327861 cites W2063859957 @default.
• W2155327861 cites W2068329523 @default.
• W2155327861 cites W2071586067 @default.
• W2155327861 cites W2087523275 @default.
• W2155327861 cites W2090761000 @default.
• W2155327861 cites W2094160256 @default.
• W2155327861 cites W2097073538 @default.
• W2155327861 cites W2099843722 @default.
• W2155327861 cites W2102371310 @default.
• W2155327861 cites W2112876622 @default.
• W2155327861 cites W2121595515 @default.
• W2155327861 cites W2122764811 @default.
• W2155327861 cites W2123135658 @default.
• W2155327861 cites W2153921667 @default.
• W2155327861 cites W2162099143 @default.
• W2155327861 cites W2165880492 @default.
• W2155327861 cites W2169790218 @default.
• W2155327861 cites W2417918518 @default.
• W2155327861 doi "https://doi.org/10.1086/597470" @default.
• W2155327861 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19275492" @default.
• W2155327861 hasPublicationYear "2009" @default.
• W2155327861 type Work @default.
• W2155327861 sameAs 2155327861 @default.
• W2155327861 citedByCount "19" @default.
• W2155327861 countsByYear W21553278612012 @default.
• W2155327861 countsByYear W21553278612013 @default.
• W2155327861 countsByYear W21553278612014 @default.
• W2155327861 countsByYear W21553278612015 @default.
• W2155327861 countsByYear W21553278612020 @default.
• W2155327861 crossrefType "journal-article" @default.
• W2155327861 hasAuthorship W2155327861A5001003748 @default.
• W2155327861 hasAuthorship W2155327861A5007133273 @default.
• W2155327861 hasAuthorship W2155327861A5014359296 @default.
• W2155327861 hasAuthorship W2155327861A5029225176 @default.
• W2155327861 hasAuthorship W2155327861A5029683655 @default.
• W2155327861 hasAuthorship W2155327861A5037926233 @default.
• W2155327861 hasAuthorship W2155327861A5043509211 @default.
• W2155327861 hasAuthorship W2155327861A5047015665 @default.
• W2155327861 hasAuthorship W2155327861A5058669821 @default.
• W2155327861 hasAuthorship W2155327861A5059398898 @default.
• W2155327861 hasAuthorship W2155327861A5062643699 @default.
• W2155327861 hasAuthorship W2155327861A5069448022 @default.
• W2155327861 hasAuthorship W2155327861A5082705335 @default.
• W2155327861 hasAuthorship W2155327861A5087175375 @default.
• W2155327861 hasBestOaLocation W21553278611 @default.
• W2155327861 hasConcept C126322002 @default.
• W2155327861 hasConcept C142462285 @default.
• W2155327861 hasConcept C203014093 @default.
• W2155327861 hasConcept C2522874641 @default.
• W2155327861 hasConcept C2776408679 @default.
• W2155327861 hasConcept C2776455275 @default.
• W2155327861 hasConcept C2776461080 @default.
• W2155327861 hasConcept C2780040827 @default.
• W2155327861 hasConcept C71924100 @default.
• W2155327861 hasConcept C90924648 @default.
• W2155327861 hasConceptScore W2155327861C126322002 @default.
• W2155327861 hasConceptScore W2155327861C142462285 @default.
• W2155327861 hasConceptScore W2155327861C203014093 @default.
• W2155327861 hasConceptScore W2155327861C2522874641 @default.
• W2155327861 hasConceptScore W2155327861C2776408679 @default.
• W2155327861 hasConceptScore W2155327861C2776455275 @default.

• next